Healthy Subject
Conditions
Keywords
CT-P41
Brief summary
A Randomized, Double-blind, Two-arm, Parallel group, Single-dose, Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety between CT-P41 and US-licensed Prolia in Healthy Male Subjects
Detailed description
This study was a randomized, double-blind, two-arm, parallel group, single-dose, phase I study designed to compare PK, PD, safety, and immunogenicity between CT-P41 and US-licensed Prolia in healthy male subjects. Subjects were randomized into a 1:1 ratio to receive a single dose (60 mg) of either CT-P41 or US-licensed Prolia. The subjects were followed up for 253 days.
Interventions
BIOLOGICALCT-P41
a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
BIOLOGICALUS-licensed Prolia
a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
Sponsors
Celltrion
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
A Randomized, Double-blind
Intervention model description
Two-arm, Parallel group
Eligibility
Sex/Gender
MALE
Age
28 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male subject, between the ages of 28 and 55 years, both inclusive 2. Subject had a body mass index (BMI) between 18.5 and 29.9 kg/m2, both inclusive, and a body weight between 50.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth. 3. Subject with total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) and serum 25-OH vitamin D ≥ 20 ng/mL (≥ 50 nmol/L)
Exclusion criteria
1. Subject was a female. 2. Subject with a hypersensitivity to any component of denosumab or dry natural rubber (a derivative of latex). 3. Subject was confirmed or suspected with infection of coronavirus disease 2019 (COVID-19) at screening, or had had contact with COVID-19 patient within 14 days from screening. 4. Subject had a medical history of and/or current medical condition that can have effect on the study. Details to be discussed with investigator as per Protocol. 1. Subjects with known risk factors for hypocalcaemia 2. Subjects with known intolerance to calcium or vitamin D supplements 3. Subjects with known infection with active hepatitis B, hepatitis C, human immunodeficiency virus, or syphilis 5. Subject had a history of and/or concurrent use of medications including any prior therapy that can have effect on the study. Details to be discussed with investigator as per Protocol. 6. Subjects have or had any therapy that might significantly affect bone metabolism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCinf | up to Day 253 | Area under the concentration-time curve from time zero to infinity (AUC0-inf) |
| AUClast | up to Day 253 | Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last) |
| Cmax | up to Day 253 | maximum serum concentration (Cmax) |
Countries
South Korea
Outcome results
None listed